Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Blood triglycerides, Intervertebral disc disorder
Clinical narrative: 4th dose 26May2022: Intervertebral disc Mar2024; This is a spontaneous report received from a Consumer or other non HCP.  A 73-year-old female patient received BNT162b2 (BNT162B2), on 26May2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 71 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Acid Reflux" (unspecified if ongoing), notes: Acid Reflux 60's; "A-fib" (unspecified if ongoing), notes: A-fib 50's; "Anxiety" (unspecified if ongoing), notes: Anxiety 60's; "Arthritis" (unspecified if ongoing), notes: Arthritis 60's; "Asthma" (unspecified if ongoing), notes: Asthma 60's; "Balance problems" (unspecified if ongoing), notes: Balance problems 80's; "Blepharitis birth" (unspecified if ongoing); "Bronchitis" (unspecified if ongoing), notes: Bronchitis 60's; "Carpal tunnel both" (unspecified if ongoing), notes: Carpal tunnel both 80's; "Cataracts both", start date: 20May2015 (unspecified if ongoing); "C-diff", start date: 20Jun2015 (unspecified if ongoing); "Cervical degeneration" (unspecified if ongoing), notes: Cervical degeneration 60's; "Concussions", start date: 2016 (unspecified if ongoing), notes: Concussions 2016/2017; "Cholesterol" (unspecified if ongoing), notes: Cholesterol 70's; "Depression" (unspecified if ongoing), notes: Depression 60's; "Dermatofibroma", start date: 2014 (unspecified if ongoing); "Deviated septum", start date: 2012 (unspecified if ongoing); "Diverticulitis" (unspecified if ongoing), notes: Diverticulitis 80's; "Dizziness" (unspecified if ongoing), notes: Dizziness 60's; "Duodenal ulcers" (unspecified if ongoing), notes: Duodenal ulcers 60's; "Esophageal polyps", start date: 2017 (unspecified if ongoing); "Exema", start date: 2016 (unspecified if ongoing); "Fibrocystic disease" (unspecified if ongoing), notes: Fibrocystic disease 60's; "Essential tremors" (unspecified if ongoing), notes: Essential tremors 60's; "Fibromyalgia" (unspecified if ongoing), notes: Fibromyalgia 60's; "Gall bladder", start date: May2002 (unspecified if ongoing); "Gastritis" (unspecified if ongoing); "Hearing loss" (unspecified if ongoing); "IBS" (unspecified if ongoing), notes: IBS 80's; "Keratosis" (unspecified if ongoing), notes: Keratosis 90's; "Migraines" (unspecified if ongoing), notes: Migraines 60's; "Osteoporosis" (unspecified if ongoing), notes: Osteoporosis 80's; "Pancreatitis", start date: 2007 (unspecified if ongoing); "Panic attacks" (unspecified if ongoing), notes: Panic attacks 60's; "Proteins deficiency", start date: Mar2004 (unspecified if ongoing); "Sinusitis" (unspecified if ongoing), notes: Sinusitis 60's; "Sleep apnea", start date: Mar2004 (unspecified if ongoing); "Stroke", start date: Mar2004 (unspecified if ongoing); "Transcranial magnetic stimulation" (unspecified if ongoing), notes: TMS 60's. The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (DOSE 1, SINGLE, Location of injection/shot: Left Arm), administration date: 03Mar2021, when the patient was 70-year-old, for COVID-19 immunization; BNT162b2 (DOSE 2, SINGLE, Location of injection/shot: Left Arm), administration date: 26Mar2021, when the patient was 70-year-old, for COVID-19 immunization; BNT162b2 (DOSE 3 (BOOSTER), SINGLE, Location of injection/shot: Left Arm), administration date: 08Nov2021, when the patient was 71-year-old, for COVID-19 immunization.  The following information was reported: INTERVERTEBRAL DISC DISORDER (non-serious) with onset Mar2024, outcome "unknown", described as "4th dose 26May2022: Intervertebral disc Mar2024". Relevant laboratory tests and procedures are available in the appropriate section.  The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.